Literature DB >> 22365399

Correlation of seven biological factors (Hsp90a, p53, MDM2, Bcl-2, Bax, Cytochrome C, and Cleaved caspase3) with clinical outcomes of ALK+ anaplastic large-cell lymphoma.

Hui Ling Li1, Xue Ping Huang, Xin Hua Zhou, Tian Hai Ji, Zi Qing Wu, Zhi Qiang Wang, Hui Yong Jiang, Fan Rong Liu, Tong Zhao.   

Abstract

OBJECTIVE: To explore correlation of seven apoptosis-related proteins (Hsp90a, p53, MDM2, Bcl-2, Bax, Cytochrome C, and Cleaved caspase3) with clinical outcomes of ALK+ anaplastic large-cell lymphoma (ALCL).
METHODS: Using immunohistochemistry and immunofluorescence double staining methods, the expressions of these seven apoptosis-associated proteins were studied to clarify their relationship with clinical outcomes of 36 ALK+ and 25 ALK-systemic ALCL patients enrolled between 1996 and 2006. The relationship of these apoptosis-regulating proteins with NPM-ALK status was also evaluated with the tyrosine inhibitor herbimycin A (HA) in vitro by immunocytochemistry, Western blotting and flow cytometric assays.
RESULTS: The presence of Hsp90α-, MDM2-, Bax-, Cytochrome C, and Cleaved caspase3-positive tumor cells was found significantly different in ALK+ and ALK-ALCLs, which was correlated with highly favorable clinical outcome. The Bcl-2- and p53-positive tumor cells were found in groups of patients with unfavorable prognosis. Inhibition of NPM-ALK by HA could reactivate the p53 protein and subsequent apoptosis-related proteins and therefore induced apoptosis in ALK+ ALCL cells.
CONCLUSION: Our results suggest that these seven proteins might be involved in apoptosis regulation and associated with clinical outcome of ALK+ systemic ALCLs. We also reveal a dynamic chain relation that NPM-ALK regulates p53 expression and subsequent apoptosis cascade in ALK+ ALCLs. Copyright Â
© 2011 The Editorial Board of Biomedical and Environmental Sciences. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22365399     DOI: 10.3967/0895-3988.2011.06.007

Source DB:  PubMed          Journal:  Biomed Environ Sci        ISSN: 0895-3988            Impact factor:   3.118


  6 in total

1.  Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas.

Authors:  Raphael Koch; Amanda L Christie; Jennifer L Crombie; Adam C Palmer; Deborah Plana; Kay Shigemori; Sara N Morrow; Alexandria Van Scoyk; Wenchao Wu; Elizabeth A Brem; J Paul Secrist; Lisa Drew; Alwin G Schuller; Justin Cidado; Anthony Letai; David M Weinstock
Journal:  Blood       Date:  2018-11-29       Impact factor: 22.113

2.  Short interfering RNA directed against the GOLPH3 gene enhances the effect of chemotherapy against oral squamous cell carcinoma by regulating Caspase3, Bcl2 and cytochrome-c expression.

Authors:  Guo-Hui Cui; Wen-Xin Li; Zhi-Yong Lin; Wei-Qun Zhang; Zhao-Hui Hu; Li Wang
Journal:  Int J Clin Exp Med       Date:  2015-08-15

3.  The relationship between MDM2 expression and tumor thickness and invasion in primary cutaneous malignant melanoma.

Authors:  Parvin Rajabi; Paridokht Karimian; Mitra Heidarpour
Journal:  J Res Med Sci       Date:  2012-05       Impact factor: 1.852

4.  Expression of Apoptosis-regulating Proteins Bcl-2 and Bax in Lymph Node Aspirates from Dogs with Lymphoma.

Authors:  K Meichner; J E Fogle; L English; S E Suter
Journal:  J Vet Intern Med       Date:  2016-03-25       Impact factor: 3.333

5.  Brahma-related gene 1 induces apoptosis in a p53-dependent manner in human rheumatoid fibroblast-like synoviocyte MH7A.

Authors:  Hongli Hou; Weipeng Xing; Wuyin Li
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

6.  BCL-W expression associates with poor outcome in patients with peripheral T-cell lymphoma not otherwise specified.

Authors:  Mario L Marques-Piubelli; Luisa M Solis; Francisco Vega; Paolo Strati; Edwin R Parra; Luis Malpica Castillo; Sushanth Gouni; Ranjit Nair; Dai Chihara; Marina Konopleva; Ignacio I Wistuba; Swaminathan P Iyer
Journal:  Blood Cancer J       Date:  2021-09-16       Impact factor: 11.037

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.